Wave of Chinese biotech deals builds with US$1.2 billion Harbour BioMed pactDeal involving an antibody asset ‘goes beyond a traditional licensing transaction’, founder and CEO says.
--------------------------------------------------------------------
Source: South China Morning Post
Published: 2026-02-23 18:15 UTC+10:00
Section: General
Factuality Score: 90
Opinion Category: Neutral
Topics: Asia, China
--------------------------------------------------------------------
Snippet:
Deal involving an antibody asset ‘goes beyond a traditional licensing transaction’, founder and CEO says
--------------------------------------------------------------------